Omega-3 Fatty Acids for Depression in Multiple Sclerosis: A Randomized Pilot Study

Area of Science:

• Neurology
• Psychiatry
• Nutritional Science

Background:

• Multiple sclerosis (MS) is a leading cause of chronic disability in young to middle-aged adults.
• Depression affects a significant portion (50-60%) of individuals with MS.
• Previous studies suggest omega-3 fatty acids may benefit unipolar depression.

Purpose of the Study:

• To evaluate omega-3 fatty acid supplementation as an add-on therapy for treatment-resistant major depressive disorder (MDD) in people with MS.
• To determine if omega-3s improve depression scores in this population.

Main Methods:

• A randomized, double-blind, placebo-controlled pilot study.
• 39 participants with MS and treatment-resistant MDD were randomized.
• Intervention involved six grams of omega-3 fatty acids daily for three months.

Main Results:

• No significant difference in achieving a 50% or greater improvement on the MADRS scale between the omega-3 group (47.4%) and placebo group (45.5%).
• The primary outcome (p = 0.30) did not meet statistical significance.
• Omega-3 supplementation was well-tolerated over the 3-month trial.

Conclusions:

• Omega-3 fatty acids, at the tested dosage and duration, did not demonstrate superior efficacy to placebo for augmenting treatment-resistant depression in MS.
• Further research may be needed to explore different dosages or patient subgroups.
• Omega-3 supplementation is a safe augmentation strategy for this population.